Brief: Transcenta Holding Receives Approval To Initiate Phase II Clinical Trial Of TST002
31/07/2023 02:53
July 31 (Reuters) - Transcenta Holding Limited
6628.HK :
* RECEIVED APPROVAL FROM CHINA CENTER FOR DRUG EVALUATION TO
INITIATE PHASE II CLINICAL TRIAL OF TST002 (BLOSOZUMAB)
Source text for Eikon: ID:nHKS7qcs2S
Further company coverage: 6628.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transcenta Holding
See all newsBrief: Transcenta Says Global Phase III Trial Of Osemitamab Approved By FDA, China, Korea Regulators
Brief: Transcenta Holding Says Unit To Sell CDMO Assets For RMB190.0 Million
Brief: Transcenta Holding To Revert Assets To Lilly For $4 Million Cash
Brief: Transcenta Therapeutics Appoints Dr. Christopher Hwang As Head Of Global Partnerships For Hicb Platform
Brief: Transcenta Announces Collaboration And Non-Exclusive Licensing Agreement With Eirgenix Inc.